Table SI. Efficacy outcomes of abrocitinib 200 mg and 100 mg at different timepoints throughout the study.

Outcomes	Total patients % W8	Abrocitinib 200 mg % W8	Abrocitinib 100 mg % W8	P value*	Total patients % W16	Abrocitinib 200 mg % W16	Abrocitinib 100 mg % W 16	P value*	Total patients % W32	Abrocitinib 200 mg % W32	Abrocitinib 100 mg % W32	P value*	Total patients % W52	Abrocitinib 200 mg % W52	Abrocitinib 100 mg % W52	P value*
EASI 75	55.8	58.6	54.6	0.72	77.8	69.6	80.6	0.31	89.4	86.7	90.2	0.69	96.3	91.7	97.6	0.31
EASI 90	27.8	24.1	29.3	0.59	51.1	52.2	50.7	0.91	62.1	60.0	62.7	0.85	79.6	66.7	83.3	0.17
EASI 100	20.2	17.2	21.3	0.69	34.4	30.4	35.8	0.79	37.9	26.7	41.1	0.31	59.3	58.3	59.5	0.94
EASI ≤ 7	70.2	68.9	70.7	0.87	84.4	78.3	86.6	0.34	93.9	93.3	94.1	0.91	98.1	100.0	97.6	1.0
EASI ≤ 3	37.5	34.5	38.7	0.69	65.6	60.9	67.1	0.58	81.8	80.0	82.3	0.83	94.4	83.3	97.6	0.17
IGA 0/1	51.9	51.7	52.0	0.97	74.4	73.9	74.6	0.95	86.3	80.0	88.2	0.41	88.9	75.0	92.8	0.09
ΔPP-NRS ≥ 4	70.4	60.7	74.3	0.18	73.8	60.8	78.4	0.10	82.8	71.4	86.0	0.20	86.8	75.0	90.2	0.18
ΔSD-NRS ≥ 4	62.2	50.0	67.1	0.11	71.5	60.8	75.4	0.17	75.0	71.4	76.0	0.73	79.2	66.7	87.8	0.06
PP-NRS 0/1	34.7	32.1	35.7	0.73	55.7	52.1	56.9	0.81	57.8	57.1	58.0	0.95	73.5	66.7	75.6	0.47
SD-NRS 0/1	62.2	64.3	61.4	0.79	78.4	73.9	80.0	0.57	85.9	85.7	86.0	0.79	98.1	91.7	100.0	0.23
MDA	18.4	21.4	15.7	0.50	42.0	39.1	43.0	0.79	50.0	50.0	50.0	1.0	66.0	58.3	68.3	0.55

Abbreviations: Δ: delta; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; MDA: Minimal Disease Activity; PP-NRS: Peak Pruritus-Numerical Rating Scale (NRS); SD-NRS: Sleep Disturbance-NRS; W: Week.
*Two-tailed Fisher's exact test.
Patients number for clinician-reported outcomes was N=104 (29 in Abrocitinib 200 mg and 75 in Abrocitinib 100 mg) at week 8, N=90 (23 in Abrocitinib 200 mg and 67 in Abrocitinib 100 mg) at week 16, N=66 (15 in Abrocitinib 200 mg and 51in Abrocitinib 100 mg) at week 32, and N=54 (12 in Abrocitinib 200 mg and 42 in Abrocitinib 100 mg) at week 52. Patients number for patient-reported outcomes was N=98 (28 in Abrocitinib 200 mg and 70 in Abrocitinib 100 mg) at week 8, N=88 (23 in Abrocitinib 200 mg and 65 in Abrocitinib 100 mg) at week 16, N= 64 (14 in Abrocitinib 200 mg and 50 in Abrocitinib 100 mg) at week 32,) and N=53 (12 in Abrocitinib 200 mg and 41 in Abrocitinib 100 mg) at week 52.